Wave Life Sciences, Inc. (WVE)

Wave Life Sciences, Inc. is trading at $3.59, down 1.10% on the session. The 50 day average sits at $4.10 and the 200 day at $7.48, which puts the stock in a downtrend. RSI is at 50.5, which reads as neutral, and MACD is bullish crossover. Volume is above average.

The nearest support is around $3.56 with resistance near $4.07, so that band frames the current range. Average daily movement is roughly $0.22, or about 6.1% of the share price, which is what any stop placement has to allow for. The overall health score of 34 out of 100 combines a trend score of 0, momentum of 64 and a risk score of 48.

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.